Pharma powerhouse AbbVie has announced that late-breaking Phase 2 results from its study of mirvetuximab soravtansine-gynx, along with carboplatin, have shown 62% response rate in ovarian cancer patients.

 

The IMGN853-0420 trial of the first-in-class antibody-drug conjugate (ADC), in combination with carboplatin, followed by maintenance monotherapy in patients with folate receptor alpha (FRα)-expressing, recurrent platinum-sensitive ovarian cancer (PSOC).

 

This multicenter, open-label trial enrolled 125 patients with FRα-positive, measurable disease who had received one prior platinum-based chemotherapy regimen. Nearly half had prior exposure to a PARP inhibitor (PARPi), a group known to potentially have reduced response to subsequent platinum therapy.

 

Patients received mirvetuximab soravtansine-gynx plus carboplatin every three weeks for six to eight cycles, followed by continuation with mirvetuximab soravtansine-gynx monotherapy.

 

The primary endpoint was confirmed objective response rate (ORR) in the ≥50% FRα subgroup after six cycles of combination therapy. Secondary endpoints included ORR in the overall population, along with duration of response (DoR), progression-free survival (PFS), and overall survival (OS).

 

"Despite being considered chemotherapy-responsive, platinum-sensitive ovarian cancer (PSOC) remains challenging to treat. With each recurrence, responses to standard platinum-based chemotherapy often diminish and patients may experience cumulative toxicities," said Daejin Abidoye, vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. 

 

"These results are encouraging and further support the potential of mirvetuximab soravtansine-gynx in PSOC as a novel treatment regimen."

 

"...strong responses in this Phase 2 study and many patients continued to experience responses during the monotherapy treatment phase," said Gottfried E. Konecny, Professor of Medicine, David Geffen School of Medicine at UCLA, and primary investigator. 

 

"These findings support further investigation of a novel treatment approach that integrates antibody drug conjugates with standard chemotherapy in patients with folate receptor alpha (FRα)-expressing recurrent platinum-sensitive ovarian cancer and in patients previously treated with PARP inhibitors who often face resistance and remain in need of additional options."